Koninklijke Philips’ $2.8bn acquisition of BioTelemetry was the medical devices industry’s biggest cross border deal of Q4 2020 as cross border deals worth $6.95bn were announced globally in the quarter, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 66.2% over the previous quarter and a drop of 14.2% when compared with the last four-quarter average of $8.1bn.
In terms of number of cross border deals, the sector saw a drop of 1.79% over the last four-quarter average with 110 deals against the average of 112 deals.
In value terms, Europe led the activity with cross border deals worth $5.39bn.
medical devices industry cross border deals in Q4 2020: Top deals
The top five medical devices industry cross border deals accounted for 64.2% of the overall value during Q4 2020.
The combined value of the top five cross border deals stood at $4.46bn, against the overall value of $6.95bn recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
1) Koninklijke Philips’ $2.8bn acquisition of BioTelemetry
2) The $700m private equity with Verily Life Sciences by Alphabet, Ontario Teachers’ Pension Plan, Silver Lake Partners and Temasek Holdings (Private)
3) Exact Sciences’ $410m acquisition of Base Genomics
4) The $286.77m private equity deal with Bioneb by GEM Global YieldSCS
5) Richter Gedeon Nyrt’s asset transaction with Janssen Pharmaceutica for $263.5m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.